Intersectin-Cdc42 Modulators for Alzheimer's Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily focus on managing cognitive symptoms without addressing the underlying pathogenic pathways, and there is an urgent need for new agents that can target and modulate these pathways to prevent and treat the disease effectively.
Innovation Solution
Administration of modulator compounds that inhibit or activate cell division control protein 42 (Cdc42) using sulfonamides, thioureas, and related aromatic compounds to modulate intersectin-Cdc42 signaling, which are administered to subjects in need of treatment for Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease focus on managing cognitive symptoms, then symptomatic relief is achieved, but the underlying pathogenic pathways are not addressed
Solution Approach 1:
The patent extracts and targets specific pathogenic elements (Cdc42 signaling pathway, intersectin-Cdc42 interaction) from the complex disease process of Alzheimer's. By isolating and modulating this specific molecular pathway with small molecule compounds, the treatment addresses the root cause rather than just symptoms, resolving the contradiction between comprehensive treatment effectiveness and approach complexity.
Solution Approach 2:
The patent uses small molecule compounds to alter the activity state of Cdc42 (switching between GTP-bound active and GDP-bound inactive states), thereby changing the functional parameters of the pathogenic pathway. This parameter change approach directly modifies the disease mechanism at the molecular level, achieving reliable treatment by addressing underlying pathology rather than symptoms.
2Reliability
If new agents target pathogenic pathways like intersectin-Cdc42 signaling, then disease prevention and treatment effectiveness improve, but the complexity of the treatment approach increases
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that mediate between the administered drug and the Cdc42 signaling pathway. These compounds serve as molecular messengers that specifically bind to and modulate the intersectin-Cdc42 interaction, enabling disease prevention through controlled pathway modulation while maintaining manageable treatment complexity through standardized compound administration.
3Productivity
If modulator compounds are administered to modulate Cdc42 activity, then behavioral and cognitive symptoms improve, but the mechanism of action becomes more complex
Solution Approach 1:
The patent segments the complex Cdc42 signaling pathway into discrete modifiable interaction points, specifically the intersectin-Cdc42 binding interface. By designing small molecules that target this specific segment of the pathway, the treatment achieves cognitive improvement through focused molecular intervention rather than broad pathway modulation, resolving the contradiction between therapeutic effectiveness and mechanism complexity.
Data Source
AI summary
Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42.